CTLA4‐Ig prevents alloantibody production and BMT rejection in response to platelet transfusions in mice

Abstract

These findings demonstrate a novel strategy using an FDA-approved drug that has the potential to prevent the clinical sequelae of alloimmunization to PLT transfusions.